Sandra J Strauss
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
Seddon B, Dehbi H, Nash S, Forsyth S, Tirabosco R, Küver K, Jamieson D, Veal G, Marples M, Ali N, Benson C, Wood Z, Rothermundt C, Cowie F, Woll P, Leahy M, Whelan J, Strauss S, Beare S. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol 2017
Sep 4, 2017Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
Sep 4, 2017Lancet Oncol 2017
Seddon Beatrice, Dehbi Hakim-Moulay, Nash Stephen, Forsyth Sharon, Tirabosco Roberto, Küver Katja, Jamieson David, Veal Gareth J, Marples Maria, Ali Nasim, Benson Charlotte, Wood Zoe, Rothermundt Christian, Cowie Fiona, Woll Penella J, Leahy Michael, Whelan Jeremy, Strauss Sandra J, Beare Sandy
Follow-up practices for high-grade extremity Osteosarcoma
Rothermundt C, Seddon B, Dileo P, Strauss S, Coleman J, Briggs T, Haile S, Whelan J. Follow-up practices for high-grade extremity Osteosarcoma. BMC cancer 2016; 16:301.
May 6, 2016Follow-up practices for high-grade extremity Osteosarcoma
May 6, 2016BMC cancer 2016; 16:301
Rothermundt Christian, Seddon Beatrice M, Dileo Palma, Strauss Sandra J, Coleman Joanne, Briggs Timothy W, Haile Sarah R, Whelan Jeremy S